The Bronchiectasis drugs in development market research report provides comprehensive information on the therapeutics under development for Bronchiectasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bronchiectasis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued products.

GlobalData tracks 30 drugs in development for Bronchiectasis by 28 companies/universities/institutes. The top development phase for Bronchiectasis is phase ii with ten drugs in that stage. The Bronchiectasis pipeline has 30 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Bronchiectasis pipeline products market are: Suzhou Regend Therapeutics, Renovion and Vast Therapeutics.

The key targets in the Bronchiectasis pipeline products market include Alpha 1 Antitrypsin (Alpha 1 Protease Inhibitor or Alpha 1 Antiproteinase or SERPINA1), Dipeptidyl Peptidase 1 (Cathepsin C or Cathepsin J or Dipeptidyl Transferase or DPPI or CTSC or EC, and 30S Ribosomal Subunit (30S RNA).

The key mechanisms of action in the Bronchiectasis pipeline product include Dipeptidyl Peptidase 1 (Cathepsin C or Cathepsin J or Dipeptidyl Transferase or DPPI or CTSC or EC Inhibitor with three drugs in Phase III. The Bronchiectasis pipeline products include seven routes of administration with the top ROA being Inhalational and eight key molecule types in the Bronchiectasis pipeline products market including Small Molecule, and Recombinant Protein.

Bronchiectasis overview

Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. This damage allows bacteria and mucus to build up in the lungs. Bronchiectasis is divided into two categories: cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss, and fever. Causes of bronchiectasis include inhaling a foreign object, cystic fibrosis, GERD, and a weakened immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants, and mucolytic agents.

For a complete picture of Bronchiectasis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.